Compounding Records — Apply record keeping requirements for compounding and hazardous materials - Mpje

SECTION 1

Historical Context & Motivation

Pharmacy compounding has ancient roots — pharmacists have prepared individualized medications for centuries — but the formal regulation of compounding records is a relatively modern development driven by patient safety crises. Throughout much of pharmacy history, compounding was the primary means of dispensing medications, and pharmacists relied on personal expertise and informal logs. However, as the pharmaceutical industry matured and large-scale manufacturing emerged in the twentieth century, compounding was increasingly marginalized until a series of contamination events and adverse outcomes demonstrated that unregulated compounding posed serious public health risks. These tragedies catalyzed federal and state legislatures into action, producing the layered regulatory framework that governs compounding documentation today.

1938 • Federal Food, Drug, and Cosmetic Act (FDCA)

Following the sulfanilamide disaster that killed over 100 people, Congress enacted the FDCA, establishing the FDA's authority over drug safety and beginning the formal distinction between manufacturing and compounding.

1997 • FDA Modernization Act (Section 503A)

Congress codified exemptions for traditional pharmacy compounding from full manufacturing requirements, provided pharmacies maintained adequate records and compounded pursuant to valid prescriptions.

2004 • USP Chapter <795> Published

The United States Pharmacopeia published standards for non-sterile compounding, including documentation requirements for master formulation records and compounding records.

2012 • New England Compounding Center (NECC) Outbreak

A fungal meningitis outbreak linked to contaminated methylprednisolone acetate injections killed 76 patients and sickened over 750 others, exposing catastrophic failures in compounding oversight and record keeping.

2013 • Drug Quality and Security Act (DQSA)

Congress responded to the NECC crisis by creating Section 503B outsourcing facilities subject to FDA cGMP inspection and establishing clearer record-keeping distinctions between 503A pharmacies and 503B outsourcing facilities.

The central question that compounding record-keeping requirements address is straightforward yet profound: how can we ensure that every compounded preparation is traceable, reproducible, and safe? Without rigorous documentation, a pharmacy cannot verify that a preparation was made correctly, investigate an adverse event, recall a defective batch, or demonstrate compliance during a board of pharmacy inspection. The regulatory answer lies in a multilayered system of master formulation records, compounding records, standard operating procedures, and hazardous drug handling documentation governed by USP chapters, state pharmacy practice acts, and federal law.

SECTION 2

Core Principles & Definitions

Compounding record-keeping is built upon a hierarchy of documentation that serves distinct but interconnected purposes. At its foundation, the system requires that every preparation can be traced from the raw ingredients through the compounding process to the final dispensed product and ultimately to the patient. This traceability principle is not merely a regulatory formality; it is a patient safety imperative that enables root-cause analysis when problems arise. Understanding the core documents and the regulatory authorities that mandate them is essential for both MPJE preparation and competent pharmacy practice.

Master Formulation Record (MFR)

A pre-approved document that serves as the "recipe" for a compounded preparation. It includes the name, strength, dosage form, ingredients with quantities, equipment needed, compounding instructions, quality control procedures, and assigned beyond-use date (BUD). The MFR must be established before the first batch is compounded.

Compounding Record (CR)

A batch-specific document created each time a preparation is compounded. It records the actual ingredients used (with lot numbers and expiration dates), the name of the compounder, the date and time of compounding, the quantity prepared, assigned BUD, and results of quality control testing. Think of it as the executed version of the MFR for a specific batch.

Standard Operating Procedures (SOPs)

Written procedures governing routine activities such as cleaning, personnel hygiene, equipment calibration, environmental monitoring, and hazardous drug handling. SOPs must be reviewed and updated regularly, and personnel must document initial training and ongoing competency assessments.

Beyond-Use Date (BUD)

The date after which a compounded preparation should not be used, determined by the pharmacy based on USP guidelines, stability data, or published literature. The BUD is distinct from a manufacturer's expiration date and must be documented in both the MFR and the CR.

Hazardous Drug Documentation

Per USP <800>, pharmacies handling hazardous drugs must maintain an assessment of risk, records of containment equipment certification, personnel training logs, exposure monitoring data, spill documentation, and medical surveillance records. These requirements overlay the standard compounding documentation.

✦

KEY TAKEAWAY

Think of compounding documentation like an airplane's flight data recorder system. The Master Formulation Record is the pre-flight checklist — a standardized protocol approved before any flight (or batch) occurs. The Compounding Record is the black box recording of that specific flight — every input, every parameter, every outcome captured in real time. If something goes wrong, investigators can reconstruct exactly what happened. Without either document, the system fails.

SECTION 3

Visual Explanation — The Documentation Hierarchy

The documentation hierarchy flows from regulatory authorities at the top through standard operating procedures and hazardous drug documentation, into the Master Formulation Record and batch-specific Compounding Record, and finally connects to patient dispensing records for full traceability.

The diagram above illustrates how compounding documentation is structured as a layered system of accountability. At the apex, regulatory authorities — including the FDA, state boards of pharmacy (BOP), the USP, and the DEA — establish the standards that drive every document below. Standard Operating Procedures and USP <800> hazardous drug documentation set the facility-wide baseline. The Master Formulation Record serves as the approved template for a given preparation, while the Compounding Record captures batch-specific execution data. Together, these documents create an unbroken chain from regulatory intent to patient outcome. Note how hazardous drug records feed into the compounding record as an overlay — hazardous compounding requires all standard documentation plus additional safety records.

SECTION 4

Regulatory Mechanism — USP Chapters, Federal Law & State Requirements

Compounding record-keeping requirements derive from three overlapping sources of authority, and understanding their interplay is essential for MPJE success. USP General Chapters set enforceable standards once adopted by state boards of pharmacy. The revised USP <795> (non-sterile compounding) and USP <797> (sterile compounding) specify the exact contents of master formulation records and compounding records, while USP <800> overlays hazardous drug handling requirements on top of both. Federal law — specifically Section 503A and Section 503B of the FDCA — distinguishes traditional pharmacy compounding from outsourcing facility production, with markedly different documentation requirements. State pharmacy practice acts then adopt, modify, or exceed these standards, creating a patchwork that the MPJE tests heavily.

USP <795> — Non-Sterile Compounding Documentation

✓ Master Formulation Record must include: official or assigned name and strength, dosage form, ingredient identities and quantities, equipment required, detailed mixing instructions, packaging and storage specifications, assigned BUD with rationale, and quality control (QC) procedures.
✓ Compounding Record must include: date and time of preparation, MFR reference, names and quantities of actual ingredients used, lot numbers and expiration dates of each ingredient, total quantity compounded, assigned BUD, compounder identification, pharmacist verification, and QC results (appearance, weight, pH, etc.).

USP <797> — Sterile Compounding Documentation

Sterile compounding adds environmental monitoring records, media fill test results, gloved fingertip sampling data, and viable and nonviable air sampling logs to the documentation requirements of <795>. The compounding record for a sterile preparation must additionally document the ISO-classified environment in which it was prepared, endotoxin testing results (for high-risk preparations), and sterility testing results where applicable. Assigned BUDs for sterile compounding are significantly more conservative than for non-sterile preparations and vary based on the category of compounded sterile preparation (CSP) — Category 1 versus Category 2 — as defined in the revised <797>.

USP <800> — Hazardous Drug Handling Documentation

USP <800> requires entities handling hazardous drugs (HDs) to maintain a comprehensive assessment of risk based on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. Documentation must include the list of HDs handled by the facility, containment primary engineering control (C-PEC) and containment secondary engineering control (C-SEC) certification records, personnel training and competency assessment logs, medical surveillance records, spill incident reports, and hazardous waste disposal manifests. The standard also requires that HDs be stored, prepared, and disposed of in designated areas, with written SOPs describing each process. Notably, USP <800> applies to all healthcare settings that handle HDs — not just pharmacies that compound them — making its documentation scope broader than <795> or <797>.

503A vs. 503B — Federal Distinctions

Requirement	503A Pharmacy	503B Outsourcing Facility
Prescription required?	Yes — patient-specific Rx	No — may compound without Rx
FDA cGMP inspection?	No (state BOP oversight)	Yes — subject to FDA cGMP
Adverse event reporting?	State-level requirements	Mandatory FDA MedWatch
Labeling requirements	Patient-specific label	Product-specific label with lot #
Record retention	Per state law (often 2–5 years)	FDA-mandated (typically ≥ 3 years)

Key regulatory distinctions between 503A traditional pharmacies and 503B outsourcing facilities

SECTION 5

Detailed Breakdown — Required Elements of Compounding Records

While the high-level distinction between the Master Formulation Record and the Compounding Record is foundational, the MPJE frequently tests knowledge of the specific data elements required in each document. The following diagram and table present the mandatory elements side by side, highlighting the critical differences between template-level and batch-level documentation.

Side-by-side comparison of the data elements required in a Master Formulation Record (left, pink border) versus a Compounding Record (right, green border). Shared elements such as BUD and ingredient information appear in both documents but serve different purposes — prescriptive in the MFR and descriptive in the CR.

⚠

MPJE High-Yield Point

A common MPJE question pattern asks whether a particular data element belongs in the MFR, the CR, or both. Remember: the MFR answers "how should this preparation be made?" while the CR answers "how was this batch actually made?" Lot numbers and expiration dates of ingredients are CR-only elements because they are batch-specific. Equipment required and compounding instructions are MFR elements because they are formula-specific.

SECTION 6

Worked Example — Completing a Compounding Record

Consider the following scenario: A community pharmacy operating under Section 503A receives a prescription for a patient-specific compound — Progesterone 100 mg vaginal suppositories, quantity of 30. The pharmacy has an existing MFR on file. The pharmacist and technician must now generate a compliant Compounding Record for this batch. Let us walk through the documentation process step by step.

Documenting a Non-Sterile Compounding Record (USP <795>)

1
Step 1 — Reference the Master Formulation Record

The compounder retrieves MFR #NS-047 ("Progesterone Vaginal Suppositories, 100 mg") and records its identifier on the new Compounding Record. The MFR specifies: Progesterone USP powder, Fattibase (suppository base), mold capacity of 2 g per suppository, and a BUD of 90 days when stored at controlled room temperature.

MFR Reference: NS-047 recorded on CR
2
Step 2 — Document Ingredients with Lot Numbers and Expiration Dates

The technician weighs Progesterone USP powder (Lot #PG-2024-0891, Exp 03/2026) — 3.0 g total for 30 suppositories (100 mg × 30 = 3,000 mg). Fattibase (Lot #FB-2024-1104, Exp 12/2025) — 57.0 g calculated by subtracting the progesterone weight from the total base needed (30 suppositories × 2.0 g/suppository = 60.0 g − 3.0 g = 57.0 g). Each ingredient's manufacturer, lot number, and expiration date are recorded on the CR.

Progesterone: 3.0 g (Lot PG-2024-0891, Exp 03/2026); Fattibase: 57.0 g (Lot FB-2024-1104, Exp 12/2025)
3
Step 3 — Record Compounding Details

The technician documents: Date of compounding (01/15/2025), time started (10:15 AM), and time completed (11:00 AM). The compounder's name and initials (Tech J. Smith, JS) are recorded. The batch is assigned an internal lot number (NS-047-20250115-01) for traceability.

Date: 01/15/2025 | Compounder: JS | Internal Lot: NS-047-20250115-01
4
Step 4 — Assign Beyond-Use Date (BUD)

Per the MFR, the BUD is 90 days when stored at controlled room temperature (20–25°C). However, the shortest ingredient expiration date is 12/2025 (Fattibase), which is beyond the 90-day window. Therefore, the assigned BUD is 04/15/2025 (90 days from compounding). If the Fattibase expiration were within the 90-day window, the BUD would be shortened accordingly — the BUD can never exceed the earliest ingredient expiration date.

Assigned BUD: 04/15/2025 (90 days from compounding, no ingredient conflict)
5
Step 5 — Quality Control and Pharmacist Verification

The technician performs QC checks per the MFR: visual inspection (all suppositories uniform in appearance, no cracks or discoloration — PASS), weight variation test (individual weights range from 1.95 g to 2.04 g, within ±10% of target — PASS), and quantity produced versus expected (30 suppositories produced, 30 expected — 100% yield). The pharmacist (RPh A. Chen, AC) performs final verification, inspects the product, reviews all documentation for completeness and accuracy, and signs the CR.

QC: PASS (visual, weight variation, yield) | RPh Verification: AC | Record complete

ℹ

Record Retention Reminder

This completed Compounding Record must be retained for the period specified by state law — typically 2 to 5 years, though some states require longer retention. The record must be readily retrievable in the event of a board of pharmacy inspection, patient complaint, or adverse event investigation. Many pharmacies now maintain electronic compounding records, which must meet the same content requirements and include audit trail functionality.

SECTION 7

Strengths, Limitations & Regulatory Comparisons

The current compounding record-keeping framework represents a significant advance in patient safety, but it is not without limitations. Understanding both the strengths and the gaps in the system is critical for pharmacists who must navigate real-world compliance challenges and for MPJE candidates who encounter questions about regulatory shortcomings and reform proposals.

Aspect	Strengths	Limitations
Traceability	Lot-level ingredient tracking enables full root-cause analysis in adverse events	Paper-based systems in smaller pharmacies may be incomplete or illegible
Reproducibility	MFRs ensure any qualified compounder can reproduce the preparation identically	No universal MFR template; variability across pharmacies reduces standardization
Regulatory Consistency	USP chapters provide uniform national standards when adopted by states	State-by-state adoption creates a patchwork; not all states adopt revised USP chapters simultaneously
Hazardous Drug Safety	USP <800> provides comprehensive personnel protection documentation requirements	Enforcement varies; some states have delayed or partially implemented <800>
Federal Oversight	503B outsourcing facilities face rigorous FDA cGMP inspection	503A pharmacies rely on state inspection frequency, which varies widely

Strengths and limitations of the current compounding record-keeping framework

✦

KEY TAKEAWAY

The compounding record-keeping system is like a building code for construction: when properly enforced, it prevents structural failures (adverse events), but its effectiveness depends entirely on consistent adoption and rigorous inspection. A building code that exists on paper but is never enforced provides a false sense of security — and the same is true for compounding documentation requirements that vary in implementation across jurisdictions. On the MPJE, recognize that the most restrictive applicable standard governs: federal law, state law, or USP standards — whichever imposes the highest requirement is the one the pharmacist must follow.

SECTION 8

Connection to Advanced Regulatory Theory — cGMP, FDA Modernization & Evolving Standards

The compounding record-keeping framework studied in this lesson exists on a continuum with current Good Manufacturing Practice (cGMP) regulations that govern pharmaceutical manufacturers. While 503A pharmacies operate under USP standards and state pharmacy practice acts, 503B outsourcing facilities are held to cGMP standards that mirror those of drug manufacturers. Understanding where compounding record-keeping sits on this spectrum — and how regulatory expectations are evolving — prepares students for advanced pharmacy law coursework, residency training, and the increasingly complex questions appearing on the MPJE.

Feature	503A Compounding (USP-Based)	503B / cGMP (FDA-Based)
Batch record complexity	Single-page CR tied to MFR	Multi-page batch production record with in-process controls
Stability testing	BUD assigned from USP defaults or literature	Formal stability studies (ICH guidelines) required for expiration dating
Environmental monitoring	Required for sterile (USP <797>) compounding	Required for all dosage forms; continuous monitoring with trend analysis
Change control documentation	MFR revision tracked informally	Formal change control system with impact assessments
Deviation documentation	Noted on CR; pharmacist determines disposition	Formal deviation reports with CAPA (corrective and preventive action) plans

Documentation complexity: USP-based compounding versus cGMP manufacturing

Looking forward, the trend is clearly toward more rigorous documentation requirements even for traditional 503A pharmacies. The revised USP <795> and <797> chapters — expected to be fully enforceable once implementation dates are finalized — significantly expand documentation expectations compared to their predecessors. Electronic compounding record systems are becoming standard, enabling automated lot tracking, real-time BUD calculations, and integrated audit trails. For MPJE candidates, the key insight is that compounding documentation is not static; it evolves with each revision of USP standards and each legislative reform. Staying current with your practicing state's adoption timeline for USP chapters is an ongoing professional obligation that extends well beyond licensure.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain the fundamental difference between a Master Formulation Record (MFR) and a Compounding Record (CR). Why are both documents necessary — wouldn't one comprehensive document suffice?

Show answer

The MFR is a pre-approved, formula-specific template that describes how a preparation should be made — it includes the standardized recipe, equipment, instructions, BUD rationale, and QC criteria. The CR is a batch-specific record documenting how a particular batch was actually made — it captures the actual ingredients used (with lot numbers and expiration dates), the identity of the compounder, and the results of QC testing. Both are necessary because the MFR ensures reproducibility across batches and personnel, while the CR ensures traceability of each individual batch. A single document would either lack the standardization of the template or the specificity of the batch record, compromising either reproducibility or traceability.

Question 2: BASIC CALCULATION

A pharmacy compounds a batch of 60 capsules, each containing 25 mg of Drug X. The compounding record must document the total quantity of Drug X weighed. If the pharmacy uses a 10% excess to account for losses during the compounding process, how many milligrams of Drug X should appear on the compounding record as the amount weighed?

Show answer

The base amount needed is 60 capsules × 25 mg/capsule = 1,500 mg. With a 10% excess, the total amount weighed is 1,500 mg × 1.10 = 1,650 mg. The compounding record should document 1,650 mg as the actual quantity of Drug X weighed, with a note referencing the MFR's instruction to prepare with a 10% excess. The expected yield (60 capsules) versus actual yield should also be documented. This excess is a standard compounding practice that must be accounted for in the documentation so that any discrepancy between ingredient weight and final product quantity is explicable during an audit.

Question 3: INTERMEDIATE

A pharmacy technician compounds a non-sterile preparation and discovers that one ingredient's lot number on the bottle does not match the lot number printed on the certificate of analysis (CoA). The technician proceeds with compounding using the ingredient. What documentation deficiency has occurred, and what should the pharmacist do upon discovering this discrepancy during final verification?

Show answer

The documentation deficiency is a failure to verify ingredient identity and traceability before compounding — the lot number mismatch between the physical container and the CoA means that the ingredient's identity, purity, and potency cannot be confirmed for that specific batch. The pharmacist should not release the compounded preparation until the discrepancy is resolved. The pharmacist must investigate whether the wrong CoA was pulled, the container was mislabeled, or the wrong ingredient was used. If the ingredient cannot be positively identified, the batch should be quarantined and potentially discarded. A deviation or incident report should be documented on the compounding record noting the nature of the discrepancy, the investigation findings, and the final disposition of the batch. This event should also trigger a review of SOPs related to ingredient receipt and verification.

Question 4: APPLIED

A hospital pharmacy compounds hazardous sterile preparations of cyclophosphamide. During a state board of pharmacy inspection, the inspector requests documentation demonstrating compliance with USP <800>. List at least five specific records or documents the pharmacy should be prepared to produce, and explain the purpose of each.

Show answer

The pharmacy should produce: (1) Assessment of risk — a written evaluation identifying all hazardous drugs handled, exposure routes, and containment strategies. (2) C-PEC and C-SEC certification records — documentation that the biological safety cabinet (BSC) and the negative-pressure room have been certified per manufacturer specifications and ISO standards (typically every 6 months for the BSC). (3) Personnel training and competency records — documentation of initial training on HD handling, use of PPE, spill management, and annual competency reassessments. (4) Medical surveillance records — baseline and periodic health assessments for personnel who handle HDs, including exposure history questionnaires and any biological monitoring results. (5) Spill documentation — incident reports for any HD spill including the drug involved, the extent of the spill, the personnel involved, the decontamination procedure followed, and any exposure that occurred. Additional records might include HD waste disposal manifests (RCRA compliance), PPE inventory and inspection logs, and surface wipe sampling results for contamination monitoring.

Question 5: CRITICAL THINKING

A 503A community pharmacy in State A has been compounding a popular topical pain cream and shipping it to patients in State B without individual prescriptions, marketing the product through a website. A patient in State B experiences an adverse reaction. Analyze the record-keeping and regulatory violations that may have occurred, considering federal law (503A vs. 503B), interstate commerce implications, and the documentation that should have been maintained but likely was not.

Show answer

This scenario presents multiple overlapping violations. First, a 503A pharmacy must compound pursuant to patient-specific prescriptions — compounding without prescriptions and marketing via a website violates the conditions of Section 503A of the FDCA. By distributing without prescriptions across state lines and advertising, the pharmacy is functionally operating as a 503B outsourcing facility or even an unlicensed manufacturer, neither of which it is registered as. Second, the pharmacy likely lacks the documentation required of a 503B facility: FDA registration, adverse event reporting systems (MedWatch), cGMP-compliant batch records, stability testing data for extended expiration dating, and product-specific labeling with lot numbers. Third, the interstate distribution means the pharmacy should be licensed in State B and subject to State B's compounding regulations, which it likely is not. For the adverse reaction, the pharmacy may be unable to produce adequate traceability documentation — without patient-specific prescriptions, there may be no link between a specific batch (compounding record) and the affected patient. The pharmacy should have maintained compounding records with assigned lot numbers linked to distribution records showing which patients received which lots. This case mirrors the circumstances that led to the NECC tragedy and the enactment of the DQSA, illustrating why the 503A/503B distinction and its documentation requirements exist.

SUMMARY

Summary — Compounding Records & Hazardous Materials Documentation

Summary

Compounding record keeping is built upon two foundational documents: the Master Formulation Record (MFR), which serves as the pre-approved recipe for a compounded preparation, and the Compounding Record (CR), which documents the batch-specific execution of that recipe. These documents are governed by USP <795> (non-sterile), USP <797> (sterile), and USP <800> (hazardous drugs), with federal distinctions between Section 503A traditional pharmacies and Section 503B outsourcing facilities establishing different documentation obligations.

Key elements of the CR include ingredient lot numbers and expiration dates, compounder identification, pharmacist verification, the assigned beyond-use date (BUD), and quality control results. For hazardous drug compounding, pharmacies must additionally maintain risk assessments, engineering control certifications, personnel training logs, medical surveillance records, and spill documentation. The governing principle for the MPJE is that the most restrictive applicable standard — whether federal, state, or USP — always controls.